U.S-based Lyndra Therapeutics, a clinical-stage biotech firm focused on making pills a thing of the past, has recently announced the results from its Phase 2 study of LYN-005, its oral ER risperidone capsule. For the records, the risperidone capsules are being developed for the treatment of schizophrenia, a serious mental disorder.
According to official reports, the data obtained from the recent trial demonstrate that LYN-005 delivered sustained therapeutic levels of the treatment over the one-week administration intervals and reduced peak drug exposure compared to IR risperidone.
Importantly, the findings from the latest clinical trial were presented in an oral presentation at the 2021 Congress of the Schizophrenia International Research Society (SIRS) on April 18th, 2021.
Commenting on the recent accomplishment, Dr. Richard Scranton, CMO of Lyndra Therapeutics cited that the acquired data, along with additional safety information from more than 200 patient dosing of the Lyndra ER capsule, add to the firm’s momentum as it looks forward to the development pathway with plans for conducting the end of latest clinical phase with the FDA.
Moreover, the company is also seeking to initiate a crucial study of LYN-005 in schizophrenia in the second half of this year.
Dr. Richard further mentioned that Lyndra is laying down its plans of demonstrating the exceptional clinical value of a novel treatment option like risperidone could have for people suffering with serious mental disorder.
Meanwhile, it is also working toward reinforcing the broad potential of Lyndra’s revolutionary oral medication platform to address medication non-adherence across an expansive range of key disease areas.
On the other hand, Dr. David Walling, CEO and principal investigator of CNS Research, Chief Clinical Officer at Apex Innovative Sciences, and a study presenter at SIRS stated that the results obtained during the Phase 2 trial of LYN-005 are highly promising as weekly oral risperidone treatment is anticipated to offer more consistent plasma drug levels relative to daily dosing.
Source Credit: https://www.businesswire.com/news/home/20210418005010/en/Lyndra-Therapeutics-Presents-Promising-Phase-2-Data-on-Once-Weekly-Oral-Risperidone-Treatment-LYN-005-in-Development-for-Schizophrenia